Everlab has closed an oversubscribed AU$65 million Series A round led by Airtree Ventures with participation from Plural, Left Lane Capital and b2venture, alongside angel investors including Australian Test captain Pat Cummins.
Founded in Melbourne in 2023, Everlab operates a digital preventative-care platform that integrates diagnostics, clinicians, prescriptions and continuous AI care.
According to the company, the platform connects with more than 1,850 provider locations, 180 active clinicians and 30 wearable devices and processes over 200,000 health reports per month.
Everlab has completed more than 40,000 consultations for about 20,000 individual patients and corporate partners, including Boston Consulting Group, BHP and Bain & Company, the company says, and has processed over 21 million biomarker test results.
The company claims that more than 25 percent of members had findings flagged that were not identified through the existing healthcare system.
The funding will be used to bolster clinical and technology infrastructure and accelerate a global rollout that the company is beginning with the UK, positioning Everlab to enter the broader consumer healthcare market worth trillions of dollars.
